Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Assenagon Asset Management S.A. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 238,522 shares of the biopharmaceutical company’s stock after buying an additional 26,235 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.31% of Xenon Pharmaceuticals worth $9,350,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Elmwood Wealth Management Inc. raised its stake in shares of Xenon Pharmaceuticals by 44.7% in the fourth quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 3,400 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Xenon Pharmaceuticals by 3.7% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,818 shares of the biopharmaceutical company’s stock valued at $1,953,000 after purchasing an additional 1,755 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Barclays PLC raised its position in Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 13,903 shares during the last quarter. Finally, Vestcor Inc acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth $327,000. 95.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on XENE. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Raymond James reissued an “outperform” rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $56.00.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now directly owns 23,573 shares in the company, valued at approximately $968,378.84. This trade represents a 17.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The disclosure for this sale can be found here. Corporate insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $38.52 on Friday. The company has a market capitalization of $2.94 billion, a price-to-earnings ratio of -13.66 and a beta of 1.20. The firm’s 50 day simple moving average is $40.48 and its 200 day simple moving average is $40.74. Xenon Pharmaceuticals Inc. has a fifty-two week low of $35.53 and a fifty-two week high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the firm earned ($0.73) EPS. Equities research analysts expect that Xenon Pharmaceuticals Inc. will post -3.13 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.